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ABSTRACT 
The aim of present study is to formulate and evaluate extended release matrix tablet of Nateglinide by direct compression method 
using different polymer like HPMC K4 and HPMC K15. Matrix tablet of nateglidine were prepared in combination with the polymer 
HPMC K4, HPMC K15, along with the excipients and the formulations were evaluated for tablet properties and in vitro drug release 
studies. Nateglinide matrix tablet prepared by using polymer such as HPMC K4 and HPMC K15,  it was found that HPMC K15 
having higher viscosity as compare to HPMC K4 therefore different concentration of polymer were studied to extend the drug 
release up to 12 h. The tablets of Nateglinide prepared by direct compression had acceptable physical characteristics and satisfactory 
drug release. The study demonstrated that as far as the formulations were concerned, the selected polymers proved to have an 
acceptable flexibility in terms of in-vitro release profile. In present the study the percent drug release for optimize batch was found to 
94.62%.  Hence it can be conclude that Nateglinide extended release matrix tablet can prepared by using HPMC. The swollen tablet 
also maintains its physical integrity during the drug release study. 
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INTRODUCTION  
Oral drug delivery systems is the most convenient mode 
of drug administration compared to other dosage forms 
due to its high patient compliance and flexibility.
1 
In 
conventional oral dosage forms drug dosage must be 
administered several times which results in fluctuating 
drug levels in plasma. These limitations of conventional 
dosage form can be overcome by formulation of 
sustained release dosage forms which provides drug 
release in an amount sufficient to maintain the 
therapeutic drug level over extended period of time, with 
release profiles sustained by the special technological 
construction and design of the system
2-3
. An alternative 
to administration of another dose is to use a dosage form 
that will provide sustained drug release, and therefore, 
maintain plasma drug concentrations. Oral extended 
release drug delivery system becomes a very promising 
approach for those drugs that are given orally but having 
the shorter half-life and high dosing frequency. 
Controlled release formulations are much desirable and 
preferred for such therapy because they offer better 
patient compliance, maintain uniform drug levels, 
reduced dose and side effects and increased margin of 
safety for high potency drugs
4
 .  Nateglinide is an oral 
antihyperglycemic agent used for the treatment of non-
insulin-dependent diabetes mellitus (NIDDM). belongs 
to the meglitinide class of short secretagogues, which act 
by binding to β cells of the pancreas to stimulate insulin 
release
5
. The short biological half-life (nearly 1.5hr) 
favours development of sustained release formulations
6
. 
Nateglinide is dosed three times daily before meals there 
is a rapid rise in plasma insulin, with peak levels 
approximately 1 hour after dosing and a fall to baseline 
by 4 hours after dosing. However, fluctuations of drug 
concentration in plasma may occur, resulting in side 
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effects or re concentration at receptor side. As the drug 
is e plasma fluctuations are minimized, therefore sustain 
dosage form of Nateglinide is desirable.  
METHODS AND MATERIALS: 
Nateglinide were obtained as a gift sample from Zydus 
cadila, Ahmadabad, India. HPMC K4 and HPMC K15 
were obtained from JCPL, Jalgaon, India. 
Microcrystalline cellulose, talc, methanol, ethanol, 
hydrochloride acid were obtained from Molychem, 
Mumbai. All other chemicals used were of analytical 
grade. 
 
 
Preparation of matrix extended release Nateglinide 
tablet: 
Tablets of nateglinide were prepared by direct 
compression Techniques. The various formulation 
batches viz., F1, F2, F3, F4 and F5 were prepared by 
using different concentration of HPMC K4 and HPMC 
K15. Microcrystalline cellulose was used as diluent in 
each batch. Talc and magnesium stearate were used as a 
glidant and lubricant respectively. The entire ingredient 
were shifted through the screen (# 80) and thoroughly 
mixed using blender. Then adding talc and magnesium 
stearate and formulation were compressed by using 
tablet punching machine (Mini press II, Chamunda, 
Ahmedabad).
  
Table 1: Formulation of Matrix Extended release Nateglinide tablets 
Batch Nateglinide  
HPMC K4 
 
HPMC K15 
 
MCC 
 
Talc 
 
Magnesium 
stearate 
F1 220 ---- 180 90 5 5 
F2 220 30 150 90 5 5 
F3 220 60 120 90 5 5 
F4 220 120 60 90 5 5 
F5 220 135 45 90 5 5 
All weights are in mg 
Compatibility of Drug and Excipients
  
The drug-excipients compatibility was studied by using 
Infrared spectroscopy. The sample of pure drug and 
other polymers over the range of 4000-400
cm-1
 using 
Fourier Transform Infrared spectrophotometer 
(Shimadzu, Japan) 
Pre-compression properties of Powder blend  
Angle of Repose
 
 
The accurately weighed powder was taken in funnel. 
The height of the funnel was adjusted that the tip of the 
funnel touched the apex of the heap of the powder. The 
powder was transfer through the funnel freely onto the 
surface. The diameter of the powder cone was measured.  
The angle of repose was calculated using the following 
equation.  
tan (θ) = h/r 
Where ‘h’ and ‘r’ are the height and radius of the 
powder cone respectively 
7
. 
Density
  
 The tap density (TBD) and loose bulk density (LBD) 
for the drug, polymers and excipients and in 
combination which was used in the research work was 
determined on the instrument. Two gram of drug 
powder was transfer into a 10 ml calibrated measuring 
cylinder. After initial volume was measured, then the 
cylinder was allowed to tap for specific time period. The 
total number of tap was calculated. 
LBD = weight of the power/volume of the packing 
TBD= weight of the powder/tapped volume of the 
packing 
The compressibility index of all ingredients was 
calculated using following equation  
Carr’s index = [(TBD – LBD) 100/ TBD] 
Hausner’s Ratio 
Hausner’s ratio was determined by following equation 8 
Hausner’s ratio = TBD/ LBD 
Evaluation of Nateglinide extended release tablets
 
1. Thickness and Diameter   
Method – Three samples were selected randomly from 
each batch and thickness was measured using venire 
caliper. Similarly one tablet from each batch was tested 
for diameter 
9
.   
2. Weight variation  
Twenty tablets were randomly selected from each batch 
and individually weighed. The average weight and 
standard deviation of 20 tablets was calculated. 
9
 
3. Hardness   
Three samples were selected from each batch and 
hardness was measured using Monsanto hardness tester. 
9
 
4. Friability 
 Friability of the tablets was measured using Roche 
friabilator. Placed twenty tablets were weighed and 
tablets were rotated for 4 minutes at 25 rpm. The tablets 
were removed and weighed again after revolution. The 
percent friability was calculated using following 
formula. 
9
 
% F= {1-(w/w0)} 100 
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Where,  
 % F = friability in percentage  
W0 = Initial weight of tablets  
W   = Weight of tablets after revolution. 
5. Drug Content 
Five tablets were weighed individually, then place in a 
morter and powdered with a pestle. An amount 
equivalent to 25mg of drug (100mg) was extracted with 
100ml of 0.1M HCl (pH1.2), stirred for 15 min using 
magnetic stirrer (Remi, Mumbai).  It was filtered 
through a filter and appropriately diluted with 0.1 M 
hydrochloric acid and the drug content using UV-VIS 
spectrophotometer at 206 nm .  
6. In-vitro dissolution release of Nateglinide
  
In vitro release of Nateglinide from formulated tablets 
was carried out 1.2 HCL for 2 hour and continued in 
phosphate buffer pH 6.8 for remaining hours. The 
studies were performed in USP dissolution apparatus II, 
(Dissolution Test Apparatus, Electrolab, India) 37 ± 0.5° 
C and 50 rpm speed. Samples were withdrawn at hourly 
interval and analyzed for Nateglinide content at 207 nm 
for PH 1.2 acid buffer and 206 nm for pH 6.8 phosphate 
buffers by using UV spectrophotometer (Shimazdu, 
Japan).
 10
 
Kinetics of in-vitro drug releas 
To study the release kinetics of In-vitro drug release, 
data was applied to kinetic models such as zero order, 
first order, Higuchi and KorsmeyerPeppas. 
Zero order: C = K0t K0 - zero-order rate constant 
expressed in units of concentration/time,  
t - time in hrs.  
First order: LogC = LogC0 – Kt / 2.303 Where, C0 - is 
the initial concentration of drug, K - first order constant, 
t - time in hrs.  
Higuchi: Qt = Kt1/2 Where Qt - amount of the release 
drug in time t, K kinetic constant, t- time in hrs.  
Korsmeyer peppas: Mt / M∞ = Kt n Where Mt - 
represents amount of the released drug at time t, M∞- Is 
the overall amount of the drug (whole dose) released 
after 12 hrs K- Is the diffusional characteristic of drug/ 
polymer system constant n- Is a diffusional exponent 
that characterizes the mechanism of release of drug. 
11
 
RESULT & DISCUSSION 
The FTIR of Nateglinide shows peaks at 1674, 1713, 
2862-3096, 3296 which was correlates with peaks of 
mixture of drug and polymer, which conclude that the 
drug is compatible with polymer. 
 
 
Figure 1: FTIR spectra of Nateglinide 
Table 2: Precompressional Parameter of the powder blend 
Sr. No. 
Angle of 
respose 
Bulk density Tapped density Hausner’s ratio Cars index 
F1 28.36±0.022   0.625±0.021 0.680±0.024 1.088±0.058 8.03±0.066 
F2 26.56±0.021 0.628±0.022 0.689±0.026 1.090±0.052 8.85±0.071 
F3  27.82±0.024 0.632±0.020 0.675±0.024  1.068±0.056 6.37±0.045 
F4 26.56±0.023 0.641±0.023 0.676±0.025 1.032±0.054 5.17±0.056 
F5 29.19±0.032 0.640±0.022 0.675±0.016 1.054±0.066 5.18±0.053 
 
The precompressional parameter shown in Table-2 
showed that all the batches having angle of repose in 
between 26-30 shows that powder having good flow 
property. All batch shows Carr’s index 5-9 therefore 
type of flow is good. Tapped density was found in range 
of 0.675-0.689.bulk density in range of 0.625-.0.641. 
All the batches shows Hausner’s ratio less than 1.25. It 
was found within the limit. 
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Table 3: Evaluation of Extended release matrix tablet of Nateglinide 
Batch 
Hardness 
(kg/cm
2
) 
Friability 
(%w/w) 
Thickness 
(mm) 
Diameter 
(mm) 
Weight 
variation test 
(mg) 
Drug 
Content 
F1 6.21±0.14 0.59±0.05 3.30±.0.057 12.00± 0.67 501±0.23 98±1.5 
F2 6.26±0.09 0.71±0.04 3.29±.0.051 12.02± 0.23 502±0.26 100±1.7 
F3 6.30±0.10 0.52±0.03 3.30± 0.053 12.03± 0.52 500±0.23 99±1.4 
F4 6.20±0.13 0.59±0.04 3.31± 0.010 12.04± 0.34 501±0.22 99±1.5 
F5 6.22±0.11 0.58±0.02 3.31± 0.056 12.02± 0.09 502±0.15 100±1.3 
 
The hardness of all the tablet batches was found from 
6.21-6.30.  The friability of all tablet batches was found 
to be in the range of 0.52-0.71 %w/w.  The diameter of 
each tablet was in range 12.00 to 12.04mm.  The 
thickness of tablet was in range 3.28-3.30mm. Weight of 
all tablets was found in range of 500-502. 
 
Table 4: Dissolution study of extended release matrix tablet of Nateglinide 
Time 
Cumalative % drug release 
F1 F2 F3 F4 F5 
30 min  4.38±0.29 4.75±0.15 8.83±0.56 11.35±0.34 12.25±0.76 
1 hour  8.22±0.70 9.32±0.56 14.02±0.52 15.43±0.55 16.60±0.58 
2 hour 10.03±0.94 11.40±0.71 15.81±0.66 21.01±0.32 22.37±0.55 
4 hour  24.32±0.80 28.03±0.38 44.07±0.23 49.93±0.56 52.31±0.42 
6 hour  29.85±0.79 39.95±0.56 53.38±0.26 61.39±0.52 62.83± 0.46 
8 hour 36.27±0.58 46.41±0.32 58.44±0.38 70.12±0.59 71.32±0.75 
10 hour 41.33±0.59 57.43±0.31 69.63±0.25 76.59±0.51 82.55±0.36 
12 hour 45.74±0.61 65.03±0.58 76.82±0.55 84.79±0.34 94.62±0.57 
 
 
Figure 2: Cumulative Percent drug release of 
Nateglinide 
There must be sufficient polymer content in a matrix 
system to form a uniform barrier. The barrier protects 
the drug from immediately releasing into the dissolution 
medium. If the polymer level is too low, a complete gel 
layer may not form, in most studies, increased polymer 
level in the formulation results in decreased drug-release 
rates. Because hydrophilic matrix tablets containing 
hydrophilic polymers absorb water and swell, the 
polymer level in the outermost hydrated layers decreases 
with time. The outermost layer of the matrix eventually 
becomes diluted to the point where individual chains 
detach from the matrix and diffuse into the bulk 
solution. The polymer chains break away from the 
matrix when the surface concentration passes a critical 
polymer concentration macromolecular disentanglement 
or surface erosion. The polymer disentanglement 
concentration is defined as the polymer concentration at 
the matrix surface. The surface concentration passes a 
critical polymer concentration of macromolecular 
disentanglement or surface erosion. It was observed that 
higher polymer levels result in slower release rate. As 
found in the concentration of HPMC K 15 decreases and 
HPMC K4 increases drug release increases. As it was 
found in F3, F4, and F5. 
Cumulative percent drug release in F5 batch at the end 
of 12 hour was found to be 94.62% while in F4, F3, F2 
and F1 was found to be 84.79%, 76.82%, 65.03%, 
45.74% respectively. 
The coefficient correlation (R2) was considered as main 
parameter for interpreting the release kinetics model. In 
the most of cases of (R2), value is higher for zero order 
than first order, so the formulation follows the zero 
order.  It also follows the Higuchi model of drug release 
along with it also follows Korsemeyer – Peppas equation 
of drug release. 
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Table 5: Kinetic treatment of data of dissolution profiles of formulations F1 – F5 
Formulations Parameter 
Mathematical models 
Zero 
order 
First 
order 
Hixoncrowell 
Korsemeyer 
peppas 
Higuchi 
plot 
F1 
R 2 0.99332 0.87964 0.80564 -0.31044654 0.9498211 
Slop  0.21944 0.0035 0.01966 1.22902064 0.1820864 
Intercept  -2.0056 0.62549 1.65277 -3.72165625 4.8092711 
F2 
R2  0.99742 0.86067 0.95966 -0.31314875 0.951878 
Slop  0.15361  0.00248 0.01395 1.00346064 0.229591 
Intercept  -0.4941  0.72354 1.97851 -3.30499091 5.354839 
F3 
R2  0.98713  0.80564 0.9157 -0.27661462 0.982296 
Slop  0.11218  0.00183 0.01029 0.85852773 0.2888078 
Intercept  6.92033 0.85765 2.69504 -2.98043542 3.7652246 
F4 
R2  0.98694 0.81289 0.91883 0.28345074 0.9842822 
Slop  0.10829 0.00184 0.01016 0.86785966 0.2997375 
Intercept  6.42055 0.83947 2.60774 -3.02264162 3.8181359 
F5 
R2 0.9805 0.80235 0.90852 0.33906093 0.9814 
Slop  0.09381 0.00175 0.0093 0.80497922 0.3467738 
Intercept  7.11308 0.8371 2.62102 -2.90255647 3.2495836 
Slop  0.11081 0.00183 0.010232 0.860626629 0.2927849 
Intercept  7.15219 0.85635 2.698301 -2.98790498 3.6531988 
 
CONCLUSION 
It could be concluded from the results, that the tablets 
consist of the HPMC K15M used alone in the 
formulation a unlabe to sustained the release of drug 
(F1). The batch F5 consist of HPMC K4M and HPMC 
K15M (F5) showed sustained release upto 12 h. Hence 
Nateglinide extended release matrix tablet can prepared 
by using HPMC to prolong the release of drug for the 
treatment of diabetes.  
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